Belatacept + Calcineurin Inhibitor
Phase 2UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Delayed Graft Function
Conditions
Delayed Graft Function, Kidney Transplant
Trial Timeline
Jun 1, 2013 → Jun 1, 2017
NCT ID
NCT01837043About Belatacept + Calcineurin Inhibitor
Belatacept + Calcineurin Inhibitor is a phase 2 stage product being developed by Bristol Myers Squibb for Delayed Graft Function. The current trial status is unknown. This product is registered under clinical trial identifier NCT01837043. Target conditions include Delayed Graft Function, Kidney Transplant.
What happened to similar drugs?
3 of 4 similar drugs in Delayed Graft Function were approved
Approved (3) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01837043 | Phase 2 | UNKNOWN |
Competing Products
8 competing products in Delayed Graft Function
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| azathioprine + sirolimus | Astellas Pharma | Approved | 43 |
| Lemborexant + Placebo | Eisai | Approved | 50 |
| Belatacept + Everolimus | Bristol Myers Squibb | Phase 1 | 21 |
| ARGX-117 | Argenx | Phase 2 | 36 |
| BG9418 (interferon beta-1a) | Biogen | Pre-clinical | 23 |
| Desflurane + Propofol | Baxter | Approved | 40 |
| Pegcetacoplan | Apellis Pharmaceuticals | Phase 3 | 41 |
| TNX-2110 + TNX-2120 + TNX-2130 + CANDIN + Diluent | Tonix Pharmaceuticals | Phase 1 | 11 |